serena williams glp-1 EXCLUSIVE: has been taking a medication to help with her recent weight loss, she revealed for the first time in an exclusive TODAY interview., The 23-time Grand Slam champion Serena Williams weight loss GLP-1

"Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss"

Tirzepatide alone was not associated with a significantly increased risk of low blood sugar, particularly when compared to insulin as seen in the SURPASS trials

Immunohistochemical staining and western blot analysis revealed that SNL increased the activation of microglia and astrocytes in the dentate gyrus of the hippocampus, along with elevated expression of pro-inflammatory cytokines such as TNF-, IL-1 and IL-6, which were significantly reversed by exendin-4 treatment [68]

Implications for employers : Employers should expect coverage of GLP-1 drugs for obesity to improve population health and employee productivity, but the return on investment from coverage is not likely to lead to lower medical costs now or in the future